ATE454447T1 - Peptidagonisten für prostata-spezifisches antigen und ihre verwendung - Google Patents
Peptidagonisten für prostata-spezifisches antigen und ihre verwendungInfo
- Publication number
- ATE454447T1 ATE454447T1 AT02789873T AT02789873T ATE454447T1 AT E454447 T1 ATE454447 T1 AT E454447T1 AT 02789873 T AT02789873 T AT 02789873T AT 02789873 T AT02789873 T AT 02789873T AT E454447 T1 ATE454447 T1 AT E454447T1
- Authority
- AT
- Austria
- Prior art keywords
- peptides
- psa
- nucleic acids
- prostate
- relates
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 239000000556 agonist Substances 0.000 title abstract 5
- 102000007066 Prostate-Specific Antigen Human genes 0.000 title abstract 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 3
- 239000013598 vector Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- -1 host cells Proteins 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000013615 primer Substances 0.000 abstract 1
- 239000002987 primer (paints) Substances 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33466901P | 2001-11-30 | 2001-11-30 | |
| US33457501P | 2001-11-30 | 2001-11-30 | |
| PCT/US2002/037805 WO2003047506A2 (en) | 2001-11-30 | 2002-11-26 | Peptide agonists of prostate-specific antigen, and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE454447T1 true ATE454447T1 (de) | 2010-01-15 |
Family
ID=26989272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02789873T ATE454447T1 (de) | 2001-11-30 | 2002-11-26 | Peptidagonisten für prostata-spezifisches antigen und ihre verwendung |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7247615B2 (de) |
| EP (1) | EP1461073B1 (de) |
| JP (1) | JP4364643B2 (de) |
| AT (1) | ATE454447T1 (de) |
| AU (1) | AU2002352913B2 (de) |
| CA (1) | CA2468258C (de) |
| DE (1) | DE60235041D1 (de) |
| DK (1) | DK1461073T3 (de) |
| ES (1) | ES2337454T3 (de) |
| WO (1) | WO2003047506A2 (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7902121B2 (en) * | 2001-07-02 | 2011-03-08 | The Board Of Trustees Of The Leland Stanford Junior University | MHC-antigen arrays for detection and characterization of immune responses |
| NZ545438A (en) * | 2003-08-21 | 2008-08-29 | Virax Dev Pty Ltd | Poxvirus vector encoding prostate specific antigens for treatment of prostate cancer |
| WO2005033278A2 (en) * | 2003-09-30 | 2005-04-14 | Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus iscom |
| CU23297A1 (es) * | 2004-11-16 | 2008-07-24 | Ct De Inmunologa A Molecular | Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer |
| US8703484B2 (en) | 2005-05-05 | 2014-04-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for detecting immune responses |
| DK1989224T3 (da) | 2006-02-24 | 2011-02-14 | Us Gov Health & Human Serv | Immunogene peptider og anvendelsesmetoder |
| US20080095790A1 (en) * | 2006-10-24 | 2008-04-24 | Perambakam Supriya M | Methods of Treating Prostate Cancer |
| CN100522460C (zh) * | 2007-12-15 | 2009-08-05 | 江西江铃底盘股份有限公司 | 一种桥壳总成的焊接夹具及焊接工艺 |
| CN102711824A (zh) * | 2009-09-14 | 2012-10-03 | 贝勒研究院 | 针对朗格汉斯细胞的疫苗 |
| US8557777B2 (en) | 2010-07-09 | 2013-10-15 | The Board Of Trustees Of The University Of Illinois | Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides |
| WO2012006634A2 (en) * | 2010-07-09 | 2012-01-12 | The Board Of Trustees Of The University Of Illiniois | Prostate specific antigen (psa) peptide therapy |
| EP2675473A1 (de) | 2011-02-15 | 2013-12-25 | Immune Design Corp. | Verfahren zur verbesserung von immunogenspezifischen immunreaktionen durch vektorisierte impfstoffe |
| EP3632463A1 (de) | 2011-04-08 | 2020-04-08 | Immune Design Corp. | Immunogene zusammensetzungen und verfahren zur verwendung der zusammensetzungen zur induzierung humoraler und zellulärer immunreaktionen |
| WO2013019445A2 (en) | 2011-07-29 | 2013-02-07 | Health Research, Inc. | Anti-angiogenic peptides and uses thereof |
| EP2833150A4 (de) | 2012-03-30 | 2016-03-23 | Univ Kyoto | Urinbiomarker zur verwendung in einem test auf prostatakrebs |
| SI2850431T1 (en) | 2012-05-16 | 2018-08-31 | Immune Design Corp. | Vaccines for hsv-2 |
| US9725494B2 (en) * | 2013-05-17 | 2017-08-08 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble CD27 (sCD27) and the use thereof |
| EA035259B1 (ru) | 2014-02-14 | 2020-05-21 | Иммьюн Дизайн Корп. | Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции |
| JP2017515841A (ja) | 2014-05-13 | 2017-06-15 | バヴァリアン・ノルディック・アクティーゼルスカブ | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ−３に対するモノクローナル抗体を用いた癌治療のための併用療法 |
| US20170196954A1 (en) | 2014-07-15 | 2017-07-13 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
| WO2017120204A2 (en) | 2016-01-05 | 2017-07-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination of histone deacetylase inhibitor and immunotherapy |
| WO2017136342A1 (en) | 2016-02-02 | 2017-08-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells |
| SG11201808457PA (en) | 2016-04-15 | 2018-10-30 | Alpine Immune Sciences Inc | Icos ligand variant immunomodulatory proteins and uses thereof |
| US11078282B2 (en) | 2016-04-15 | 2021-08-03 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| CN110088127A (zh) | 2016-07-28 | 2019-08-02 | 高山免疫科学股份有限公司 | Cd155变体免疫调节蛋白及其用途 |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| KR102692556B1 (ko) | 2017-03-16 | 2024-08-09 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Pd-l1 변이체 면역조절 단백질 및 그의 용도 |
| WO2018170023A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
| CN110662758A (zh) | 2017-03-16 | 2020-01-07 | 高山免疫科学股份有限公司 | Cd80变体免疫调节蛋白及其用途 |
| CN110506060B (zh) | 2017-03-30 | 2024-05-07 | 昆士兰大学 | 嵌合分子及其用途 |
| US11273211B2 (en) | 2017-08-24 | 2022-03-15 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant MVA and an antibody |
| EP3687561A4 (de) | 2017-09-01 | 2021-06-09 | The Australian National University | Immunregulatorische moleküle und deren verwendung |
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| PT3697810T (pt) | 2017-10-18 | 2026-02-19 | Alpine Immune Sciences Inc | Proteínas imunomoduladoras de ligandos icos variantes e composições e métodos relacionados |
| BR112020013236A2 (pt) | 2018-01-03 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| KR20210089146A (ko) | 2018-09-19 | 2021-07-15 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 변이체 cd80 단백질 및 관련 구축물의 방법 및 용도 |
| AU2019354101B2 (en) | 2018-10-05 | 2026-02-19 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant MVA and an immune checkpoint antagonist or agonist |
| BR112021009856A8 (pt) | 2018-11-20 | 2021-09-08 | Bavarian Nordic As | Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l |
| EP3887394A2 (de) | 2018-11-30 | 2021-10-06 | Alpine Immune Sciences, Inc. | Cd86-variante immunmodulatorische proteine und verwendungen davon |
| JP2022529059A (ja) | 2019-04-17 | 2022-06-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントｉｃｏｓリガンド（ｉｃｏｓｌ）融合タンパク質の方法および使用 |
| AU2020387646A1 (en) | 2019-11-20 | 2022-05-19 | Bavarian Nordic A/S | Recombinant MVA viruses for intratumoral and/or intravenous administration for treating cancer |
| BR112022022524A2 (pt) | 2020-05-08 | 2022-12-13 | Alpine Immune Sciences Inc | Proteínas imunomoduladoras inibidoras de april e baff com e sem uma proteína inibidora de células t e métodos de uso das mesmas |
| IL308336A (en) | 2021-05-07 | 2024-01-01 | Alpine Immune Sciences Inc | Methods of dosing and treatment with TACI-FC modulatory fusion protein |
| WO2023118508A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| US20250243260A1 (en) | 2022-03-07 | 2025-07-31 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses |
| JP2025535041A (ja) | 2022-10-04 | 2025-10-22 | アルパイン イミューン サイエンシズ インコーポレイテッド | 自己抗体介在疾患の治療における使用のための変異ｔａｃｉ－ｆｃ融合タンパク質 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6946133B1 (en) * | 1996-03-20 | 2005-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Prostate specific antigen oligo-epitope peptide |
| WO1998059073A1 (en) * | 1997-06-20 | 1998-12-30 | Mayo Foundation For Medical Education And Research | Method for detection of breast cancer |
| ATE530193T1 (de) | 2000-05-12 | 2011-11-15 | Northwest Biotherapeutics Inc | Verfahren zur steigerung der klasse i präsentation von exogenen antigene durch humane dendritische zellen |
-
2002
- 2002-11-26 AT AT02789873T patent/ATE454447T1/de active
- 2002-11-26 EP EP02789873A patent/EP1461073B1/de not_active Expired - Lifetime
- 2002-11-26 DE DE60235041T patent/DE60235041D1/de not_active Expired - Lifetime
- 2002-11-26 US US10/497,003 patent/US7247615B2/en not_active Expired - Lifetime
- 2002-11-26 DK DK02789873.3T patent/DK1461073T3/da active
- 2002-11-26 WO PCT/US2002/037805 patent/WO2003047506A2/en not_active Ceased
- 2002-11-26 AU AU2002352913A patent/AU2002352913B2/en not_active Expired
- 2002-11-26 ES ES02789873T patent/ES2337454T3/es not_active Expired - Lifetime
- 2002-11-26 JP JP2003548767A patent/JP4364643B2/ja not_active Expired - Lifetime
- 2002-11-26 CA CA2468258A patent/CA2468258C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002352913A1 (en) | 2003-06-17 |
| US7247615B2 (en) | 2007-07-24 |
| CA2468258C (en) | 2011-10-11 |
| EP1461073A2 (de) | 2004-09-29 |
| DE60235041D1 (de) | 2010-02-25 |
| WO2003047506A2 (en) | 2003-06-12 |
| JP4364643B2 (ja) | 2009-11-18 |
| AU2002352913B2 (en) | 2008-05-29 |
| CA2468258A1 (en) | 2003-06-12 |
| DK1461073T3 (da) | 2010-03-29 |
| EP1461073B1 (de) | 2010-01-06 |
| JP2005511037A (ja) | 2005-04-28 |
| US20050054575A1 (en) | 2005-03-10 |
| EP1461073A4 (de) | 2007-01-17 |
| WO2003047506A3 (en) | 2004-07-15 |
| ES2337454T3 (es) | 2010-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE454447T1 (de) | Peptidagonisten für prostata-spezifisches antigen und ihre verwendung | |
| HUP0401591A2 (hu) | Új receptor-nukleinsavak és- polipeptidek | |
| WO2005056600A3 (en) | Monoclonal antibodies that bind or neutralize dengue virus | |
| MXPA04008077A (es) | Anticuerpos ant-a° y su uso. | |
| AU2014317884B2 (en) | Immune system modulators | |
| WO2001055327A3 (en) | Nucleic acids, proteins, and antibodies | |
| WO2001055317A8 (en) | Nucleic acids, proteins, and antibodies | |
| WO2003034903A3 (en) | Psma antibodies and protein multimers | |
| MX2009013824A (es) | Proteinas de enlace de antigeno que enlazan par-2. | |
| AU2020200990A1 (en) | Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies | |
| AU2014317884A1 (en) | Immune system modulators | |
| MX2023006773A (es) | Composiciones de agentes de union a antigenos de guanilato ciclasa c (gcc) y metodos de uso de estos. | |
| US20130296252A1 (en) | Muc18 targeting peptides | |
| MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
| MXPA05007940A (es) | Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1. | |
| AU2016229309B2 (en) | Immune system modulators and compositions | |
| WO2003068800A3 (en) | Isolated peptides which bind to hla molecules and uses thereof | |
| WO2003103474A3 (en) | DIAGNOSTIC MARKERS FOR NERVOUS SYSTEM DISORDERS | |
| AU2002336244A1 (en) | Trp2 isoform trp2-6b containing hla-a2-restricted epitopes | |
| TW200500465A (en) | Novel humanized anti-vap-1 monoclonal antibody | |
| WO2001055313A3 (en) | Nucleic acids, proteins, and antibodies | |
| ATE527354T1 (de) | Diabetogene epitope | |
| HK1248574B (en) | Immune system modulators and compositions | |
| UA84840C2 (ru) | Нуклеотидная последовательность, которая кодирует tolc, плазмида, протеин или пептид, бактерия, фармацевтический препарат, диагностический набор и связующее средство для препаратов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1461073 Country of ref document: EP |